Developmental delay –motor (mild, moderate or severe) · women at risk of preterm birth
Dexamethasone showed no clear difference in developmental delay –motor (mild, moderate or severe) compared with betamethasone – child outcomes (moderate certainty).
1 finding from 1 review
Intellectual impairment: developmental delay – cognitive or language (mild, moderate or severe) · women at risk of preterm birth
Dexamethasone showed no clear difference in intellectual impairment: developmental delay – cognitive or language… compared with betamethasone – child outcomes (moderate certainty).
1 finding from 1 review
Cerebral palsy · women at risk of preterm birth
Dexamethasone showed no clear difference in cerebral palsy compared with betamethasone – child outcomes (low certainty).
1 finding from 1 review
Any known death after randomisation (fetal, neonatal, child, child as adult) · women at risk of preterm birth
It is very uncertain whether dexamethasone: oral changes any known death after randomisation (fetal, neonatal, child, child… compared with intramuscular – fetal/neonatal outcomes (very low certainty).
1 finding from 1 review
Respiratory distress syndrome · women at risk of preterm birth
It is very uncertain whether dexamethasone: oral changes respiratory distress syndrome compared with intramuscular – fetal/neonatal outcomes (very low certainty).
1 finding from 1 review
Intraventricular haemorrhage · women at risk of preterm birth
It is very uncertain whether dexamethasone: oral changes intraventricular haemorrhage compared with intramuscular – fetal/neonatal outcomes (very low certainty).
1 finding from 1 review
Necrotising enterocolitis · women at risk of preterm birth
It is very uncertain whether dexamethasone: oral changes necrotising enterocolitis compared with intramuscular – fetal/neonatal outcomes (very low certainty).
1 finding from 1 review
Chorioamnionitis · women at risk of preterm birth
Dexamethasone showed no clear difference in chorioamnionitis compared with betamethasone – maternal outcomes (moderate certainty).
1 finding from 1 review
Chronic lung disease · women at risk of preterm birth
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Any known death after randomisation (fetal, neonatal, child, child as adult) · women at risk of preterm birth
It is very uncertain whether betamethasone acetate plus phosphate changes any known death after randomisation (fetal, neonatal, child, child… compared with betamethasone phosphate – fetal/neonatal outcomes (very low certainty).
1 finding from 1 review
Respiratory distress syndrome · women at risk of preterm birth
It is very uncertain whether betamethasone acetate plus phosphate changes respiratory distress syndrome compared with betamethasone phosphate – fetal/neonatal outcomes (very low certainty).
1 finding from 1 review
Intraventricular haemorrhage · women at risk of preterm birth
It is very uncertain whether betamethasone acetate plus phosphate changes intraventricular haemorrhage compared with betamethasone phosphate – fetal/neonatal outcomes (very low certainty).
1 finding from 1 review
Necrotising enterocolitis · women at risk of preterm birth
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Chronic lung disease · women at risk of preterm birth
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Any known death after randomisation (fetal, neonatal, child, child as adult) · women at risk of preterm birth
It is very uncertain whether betamethasone 12‐hourly changes any known death after randomisation (fetal, neonatal, child, child… compared with 24‐hourly dosing – fetal/neonatal outcomes (very low certainty).
1 finding from 1 review
Respiratory distress syndrome · women at risk of preterm birth
It is very uncertain whether betamethasone 12‐hourly changes respiratory distress syndrome compared with 24‐hourly dosing – fetal/neonatal outcomes (very low certainty).
1 finding from 1 review
Intraventricular haemorrhage · women at risk of preterm birth
It is very uncertain whether betamethasone 12‐hourly changes intraventricular haemorrhage compared with 24‐hourly dosing – fetal/neonatal outcomes (very low certainty).
1 finding from 1 review
Chronic lung disease · women at risk of preterm birth
It is very uncertain whether betamethasone 12‐hourly changes chronic lung disease compared with 24‐hourly dosing – fetal/neonatal outcomes (very low certainty).
1 finding from 1 review
Maternal puerperal sepsis · women at risk of preterm birth
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Necrotising enterocolitis · women at risk of preterm birth
It is very uncertain whether betamethasone 12‐hourly changes necrotising enterocolitis compared with 24‐hourly dosing – fetal/neonatal outcomes (very low certainty).
1 finding from 1 review